reason report
outlook improv ew end year momentum
bottom line ew report adjust sale
y/i y/i ex fx adjust sale
y/i y/i ex fx predict quarterli tavr
meaning beat consensu entir driven thv transcathet
heart valv importantli ew saw sustain momentum
exit year thv sale growth acceler almost
point comp-adjust basi global thv sale acceler
nearli point comp-adjust basi -- us -- bode well
least remaind remain cautiou around
durabl growth momentum howev medium-to-
longer term data point show taper physician expect
project volum recent medacorp
survey link project y/i y/i vs consensu
y/i y/i respect ew share inevit move higher
tomorrow -- especi recent share sell-off -- street
estim deservedli environ
estim upsid seem critic sustain top-tier valuat like ew
share enjoy need tangibl bullish data point
volum growth vs see medacorp physician
survey continu believ tavr market one
exciting/faster-grow market within med-tech ew retain
leadership posit bit cautiou pace
increment adopt ramp base data point ew
one solid compani within large-cap med-tech top-tier
growth leadership posit massiv highli under-penetrated
market price-to-earnings vs ep estim think
well-reflect current valuat -- without high convict
estim upsid -- thu continu rate share mp
price-to-earnings multipl ep estim pt assum stabl
multipl current ep estim
well large-cap group averag think
ew market-lead posit highli under-penetrated total
address market justifi premium valuat rel rest
large-cap med-tech group mp op mp
op mp op op think premium
seem unlik thu would reli sole estim
upsid push pt meaning higher
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
year price history/av daili volume mil ew
compani inform svb leerink llc research
revenu mm non-gaap dilut adjust ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
higher manag increas sale guidanc vs
compani previou estim ep guid move
vs previou guidanc
sale estim move slightli higher y/i
previous ep also move
higher period
takeaway call beyond thv out-performance
investor could also focu mitral perform quarter
well outlook mitral fell short compani origin
guidanc year larg expect recent guid
lower call earli decemb analyst meet
importantli manag reiter sale guid
mitral given mitral next leg growth ew
stori -- compani believ opportun --
investor disproportion focus busi rel
overal import sale current manag also reiter
confid reach transcathet mitral tricuspid therapi
tmtt mileston discuss recent analyst day includ
execut four pivot studi early-tavr ew gave meaning
updat vs recent earli decemb enrol
expect complet recal clinic trial studi
tavr asymptomat aortic stenosi patient ew past
state make half total sever aortic stenosi patient
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul intermedi low risk occur
slower pace already-elev investor expect continu believ
intermedi risk -- low risk -- indic repres massiv increment market
opportun also believ ramp patient slower saw
inoper high risk low risk ramp like even slower seen
term need seemingli intens market develop effort drive referr
move risk curv particularli younger less sick portion intermedi
risk patient popul low risk patient popul potenti increas surgeon
pushback less sick patient popul heart member ramp effort
preserv surgic busi
near-to-medium term ew still beat rais stori share current trade
earn becom increasingli difficult argu meaning multipl
expans
price target appli price-to-earnings multipl ep estim
pt assum stabl multipl current ep estim
well large-cap group averag also think ew market-lead
posit highli under-penetrated total address market justifi premium valuat
rel rest large-cap med-tech group mp op mp op
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
revenu
consensu incom statement item includ contributor factset
total transcathet mitral tricuspid
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
revenu
consensu incom statement item includ contributor factset
total transcathet mitral tricuspid therapi
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
sg sale sale
underli growth
top neg
fx downsid
sale
growth neg
fx downsid
top
neg impact
top
impact
impact
impact
high end
high end
high end
high end
top
higher end
higher end
higher end
higher end
around top
around top
top end
top end
minim sale
tmtt
tmtt
tmtt
tmtt
clinic trial prospect random control multi-cent studi patient
random receiv either transcathet aortic valv replac tavr edward
sapien thv clinic surveil patient stratifi whether abl
perform treadmil stress test patient posit stress test follow registri
collect data subsequ treatment mortal applic
ew plan enrol patient year older
 januari receiv fda approv patient across center begin enrol later
 octob trial continu enrol
 decemb analyst day patient enrol date ew expect complet enrol
 octob trial half enrol ew expect complet enrol
 ew analyst day decemb ew re-affirmed expect complet enrol
sapien pulmon
 sapien pulmon valv expand indic pulmon rvot conduit patch patient
 alterra adapt present pulmon patch patient expand treatabl popul
 decemb pivot trial plane
resili trial evalu
durabl aortic
resilia tissu subject
object observ trial determin time valv failur due valv deterior
requir re-intervent collect/investig earli potenti predictor valv durabl
calcif hemodynam deterior resilia tissu valv
multicent prospect non-random single-arm observ trial subject evalu year
post-impl two hundr fifti total subject fifteen investig site enrol
primari outcom measur time bioprosthet valv failur due valv deterior time frame year post-impl
 ew analyst day decemb ew plan start pivot trial next month
-a januari ew recent paus enrol clinic trial perform design valid test featur
valv ew see posit result test clinic trial expect resum enrol paus
also postpon start ce mark trial
 juli ew expect resum enrol year
 octob ew decid includ number signific enhanc valv serv
broader group patient
 decemb expect enrol resum enhanc made
octob ew decid commerci valv system incorpor number enhanc ew
current ce mark expect
 decemb slimmer devic profil new transap deliveri system expect introduc
complet septemb patient enrol
sapien mitral replac novel dock featur allow treatment wide
rang annulu size low-profil deliveri system specif design transfemor
 follow-up pend month year annual year
 ew analyst day decemb pivot trial transfemor mitral replac approv fda
ew plan initi enrol
ew plan enrol multi-cent prospect single-arm non-random studi
-a plan enrol patient
 ew analyst day decemb ew initi earli feasibl studi plan continu enrol
 januari ew receiv fda approv earli feasibl studi
ce mark studi subject complet document reduct sever mitral
regurgit mr improv minut walk test subject moder sever mr ew
alreadi ce mark product europ commerci launch on-go
 record commerci sale europ
 present year follow-up data tct
cardioband repair studi transcathet repair mitral insuffici cardioband system
repair cardioband transcathet cardioband indic treatment
secondari function mitral regurgit fmr cardioband transcathet system deploy
beat heart transsept approach cardioband deploy along posterior
annulu mitral valv mv adjust trans-esophag guidanc beat
studi object test efficaci cardioband improv mr heart failur symptom
patient symptomat new york heart associ nyha class iii-iva sever mr post-
 pivot trial activ trial prospect random multicent trial patient
clinic signific function mitral regurgit random receiv either transcathet
mitral valv repair edward cardioband system plu guidelin direct medic therapi
gdmt gdmt alon patient seen follow-up visit discharg day month
annual year
purpos studi assess safeti perform clinic outcom edward
pascal transcathet mitral valv repair tmvr multi-cent multi-n
prospect singl arm safeti perform clinic outcom studi
complet enrol complet may ew actual enrol patient vs patient anticip
reduct sever mr day least one categori scale time frame day
on-go ew plan enrol patient
complet decemb publish posit data lancet present month result tct
ew plan enrol patient earli feasibl studi
 octob ew begun enrol ce mark trial expect expand trial multipl center
remaind year
 februari ew expect complet enrol
 decemb expect product launch
 decemb expect product launch
 control launch eu start continu
 februari ew track initi pascal trial
 juli ew continu treat patient feasibl studi
ew plan enrol patient
 juli studi statu chang activ recruit recruit
purpos studi assess safeti perform clinic outcom edward
pascal transcathet mitral valv repair tmvr multi-cent multi-n
prospect singl arm safeti perform clinic outcom studi
composit major advers event mae defin cardiovascular mortal stroke myocardi infarct new need renal
replac therapi sever bleed re-intervent studi devic relat complic day time frame
primari endpoint assess day
repair treat broad
spectrum mitral regurgit
repair treat broad
spectrum mitral regurgit
clinic trial prospect random control multi-cent studi patient
random receiv either transcathet aortic valv replac tavr edward
sapien thv clinic surveil patient stratifi whether abl
perform treadmil stress test patient posit stress test follow registri
collect data subsequ treatment mortal applic
clasp iid prospect multicent random control pivot trial evalu safeti
effect transcathet mitral valv repair edward pascal transcathet
mitral valv repair system compar abbott mitraclip patient degen mitral
 octob ew receiv fda approv initi pascal pivot trial
ew plan enrol patient
 ew analyst day decemb ew plan fulli enrol clasp iid end
pascal inferior mitraclip respect proport patient major advers event mae primari
safeti endpoint composit major advers event mae time frame day
pascal inferior mitraclip respect proport patient mr sever reduct measur
echocardiographi use scale time frame month
 ew analyst day decemb ew expect fda approv product launch time-frame
 ew analyst day decemb ew enrol random studi clasp iid iif iitr
clasp iid iif trial record page clinicaltri gov estim enrol patient combin
estim clasp iif enrol patient
 ew analyst day decemb ew enrol random studi clasp iid iif iitr
 decemb ew plan initi pivot trial late
cardioband activ enrol ce mark trial expand indic tricuspid patient target
ce mark approv
complet juli ew complet enrol ce mark trial cardioband tricuspid physician
 patient day earli readout present tct demonstr high procedur success good safeti
 decemb expect eu introduct late
 juli ew receiv ce mark
 earli feasibl studi multi-cent prospect single-arm non-random studi
design evalu safeti perform edward cardioband tricuspid valv
start
 februari ew receiv approv begin earli feasibl studi work activ center
 juli ew track begin earli feasibl studi may limit suppli
ew plan enrol patient
 januari ew increas estim enrol
 ew analyst day decemb ew plan enrol tricuspid earli feasibl studi
cardioband transcathet cardioband market system approv
treatment secondari function mitral regurgit fmr ce grant septemb
cardioband annuloplasti band similar surgic annuloplasti howev deploy
beat heart transven approach ce mark studi subject
complet document signific reduct sever mr improv qualiti life
minnesota live heart failur questionnair mlhfq ney york heart associ nyha
minut walk test subject moder sever mr aim current studi
evalu cardioband annuloplasti system repair tricuspid regurgit
on-go ew plan enrol patient
spacer trial repair
use edward tricuspid
purpos studi assess safeti devic perform edward tricuspid
transcathet repair patient clinic signific symptomat tricuspid regurgit
high surgic risk standard tricuspid repair/replac studi multi-cent
intern prospect singl arm safeti studi enrol subject assess clinic follow-
month month year annual year post implant procedur
evoqu tricuspid
edward announc structur up-front invest harpoon pioneer beating-heart repair
degen mitral regurgit dmr exclus option acquir compani
dec edward announc acquisit harpoon medic inc million cash
potenti million pre-specifi milestone-driven payment next
primari endpoint studi assess mortal cardiac treat cohort day compar literatur
deriv perform goal base high-risk surgic outcom tricuspid repair/replac
 ew analyst day decemb ew plan initi earli feasibl studi tricuspid
 decemb ce mark expect year end earli
 april ew learn complic three treat earli clinic studi may influenc
time commerci launch
 ew analyst day decemb ce mark expect come week
 februari ew expect european launch
 octob ew provid updat timelin
 juli ew expect european launch
 ew analyst day decemb ce mark expect come week
sutrafix id design streamlin procedur replac manual knot tie autom sutur
fasten four pre-load configur secur surgic heart valv ring open
minim invas procedur
konect resilia aortic-valv conduit design patient undergo complex root aortic
valv procedur ew estim could potenti benefit patient
